Effect of pioglitazone on arterial baroreflex sensitivity and sympathetic nerve activity in patients with acute myocardial infarction and type 2 diabetes mellitus

Journal of Cardiovascular Pharmacology
Hiroshi YokoeToshiji Iwasaka

Abstract

Pioglitazone has been shown to reduce the occurrence of fatal and nonfatal myocardial infarction (MI) in type 2 diabetes mellitus (DM). However, the mechanisms of such favorable effects remain speculative. The aim of this study was to investigate the effect of pioglitazone on arterial baroreflex sensitivity (BRS) and muscle sympathetic nerve activity (MSNA) in 30 DM patients with recent MI. Patients were randomly assigned to those taking pioglitazone (n = 15) and those not taking pioglitazone (n = 15) at 4 weeks after the onset of MI. BRS, MSNA, calculated homeostasis model assessment of insulin resistance index (HOMA-IR), and plasma adiponectin were measured at baseline and after 12 weeks. Pioglitazone increased plasma adiponectin (from 6.9 ± 3.3 μg/dL to 12.2 ± 7.1 μg/dL) and reduced HOMA-IR (from 4.0 ± 2.2 to 2.1 ± 0.9). In the pioglitazone group, MSNA decreased significantly (from 37 ± 7 bursts/min to 25 ± 8 bursts/min) and BRS increased significantly (from 6.7 ± 3.0 to 9.9 ± 3.2 ms/mm Hg) after 12 weeks. Furthermore, a significant relationship was found between the change in MSNA and HOMA-IR (r = 0.6, P = 0.042). Thus, pioglitazone decreased the sympathetic nerve traffic through the improvement of insulin resistance in DM ...Continue Reading

References

Mar 1, 1988·European Heart Journal·K Malmberg, L Rydén
Mar 1, 1985·The Journal of Clinical Investigation·M ModanZ Fuchs
Sep 1, 1985·Hypertension·C P LucasG M Reaven
Jan 1, 1983·Advances in Metabolic Disorders·M Van Houten, B I Posner
Feb 7, 1983·Brain Research·A SauterK Ueta
Jan 1, 1995·Clinical and Experimental Hypertension : CHE·M S MuntzelA L Mark
May 15, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·O BarbierB Staels
Jan 10, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·Y NagaiG Nomura
Jan 14, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·David S CalnekC Michael Hart
Oct 8, 2009·Current Opinion in Lipidology·Nora E StraznickyElisabeth A Lambert
Jun 16, 2010·Autonomic Neuroscience : Basic & Clinical·Daisuke KobayashiShuichi Kaneko
Jul 8, 2010·Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine·Kenneth M MaddenDarcye Cuff

❮ Previous
Next ❯

Citations

Jul 21, 2012·The Journal of Pharmacology and Experimental Therapeutics·Ding ZhaoVirginia L Brooks
Jul 9, 2014·Hypertension·Alfredo GamboaItalo Biaggioni
May 17, 2015·American Journal of Physiology. Heart and Circulatory Physiology·Elisabeth A LambertGavin W Lambert
Feb 26, 2019·International Heart Journal·Masaya SakamotoYosuke Kayama
May 9, 2019·Hypertension·Elisabeth A LambertGavin W Lambert
Apr 2, 2021·Circulation Research·Shi FangCurt D Sigmund
Jun 3, 2021·Journal of Clinical Medicine·Mirko Parasiliti-CaprinoMauro Maccario

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.